Physician profile
Victor Pazos
NPI 1215990437
$10,745.50
in general payments reported to CMS, 2019-2025
41 companies · $1,104 in 2025
The $1,104 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,666 · 2020: $934 · 2021: $1,739 · 2022: $1,893 · 2023: $1,647 · 2024: $1,763 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,479 · Education: $34.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,479.24 |
| Education | $34.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,533.62 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,155.95 | 2019-2024 | Xarelto |
| Medtronic, INC. | $1,018.51 | 2021-2025 | Cobalt Dr Mri Surescan, Mycarelink, Symplicity G3 |
| Amgen INC. | $988.52 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $739.07 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $718.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $614.60 | 2019-2024 | Farxiga, Brilinta, Wainua |
| Sanofi-Aventis U.S. LLC | $527.39 | 2019-2024 | |
| Boston Scientific Corporation | $479.13 | 2019-2025 | Watchman, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $385.68 | 2021-2025 | |
| Amarin Pharma, INC. | $308.37 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $295.85 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $193.09 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $184.97 | 2020-2023 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $148.79 | 2019-2024 | Lifevest |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Pazos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.